JP2006502229A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006502229A5 JP2006502229A5 JP2004543576A JP2004543576A JP2006502229A5 JP 2006502229 A5 JP2006502229 A5 JP 2006502229A5 JP 2004543576 A JP2004543576 A JP 2004543576A JP 2004543576 A JP2004543576 A JP 2004543576A JP 2006502229 A5 JP2006502229 A5 JP 2006502229A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- subunit
- fatty acid
- acid amide
- amide hydrolase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 7
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 4
- 229910052757 nitrogen Chemical group 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- -1 chloro, hydroxyl Chemical group 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 229940122746 Fatty acid amide hydrolase inhibitor Drugs 0.000 claims 4
- 239000003940 fatty acid amidase inhibitor Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 0 CCC(CC)C1=N*(*)=C(*)*1 Chemical compound CCC(CC)C1=N*(*)=C(*)*1 0.000 description 32
- JZMJPQSSQDZJOZ-OUOSTHCTSA-N CC/C=C(/CC)\c1ncc(/C(/S)=N/C=C\C)[o]1 Chemical compound CC/C=C(/CC)\c1ncc(/C(/S)=N/C=C\C)[o]1 JZMJPQSSQDZJOZ-OUOSTHCTSA-N 0.000 description 2
- POTKLASIBLXGKX-UHFFFAOYSA-N CCC(C)Cc1nc(-c2cnc[o]2)c[o]1 Chemical compound CCC(C)Cc1nc(-c2cnc[o]2)c[o]1 POTKLASIBLXGKX-UHFFFAOYSA-N 0.000 description 2
- GZJXHVJMBUKZFU-BXIAMOKOSA-N CCC(CC)/C(/C)=N/C=C(/c1c[o]cc1)\O Chemical compound CCC(CC)/C(/C)=N/C=C(/c1c[o]cc1)\O GZJXHVJMBUKZFU-BXIAMOKOSA-N 0.000 description 2
- ULKQEZAYRDJPNB-UHFFFAOYSA-N CCC(c1ncc(-c2cnc[o]2)[o]1)=C=C Chemical compound CCC(c1ncc(-c2cnc[o]2)[o]1)=C=C ULKQEZAYRDJPNB-UHFFFAOYSA-N 0.000 description 2
- OXKIWEHCLSLLMB-UHFFFAOYSA-N CCC1(Cc2nc(-c3ncc[n]3C)c[o]2)CC1 Chemical compound CCC1(Cc2nc(-c3ncc[n]3C)c[o]2)CC1 OXKIWEHCLSLLMB-UHFFFAOYSA-N 0.000 description 2
- JUGSPWDXQAPNQS-UHFFFAOYSA-N CCCC(CC)c1nc(-c2ncc[s]2)c[o]1 Chemical compound CCCC(CC)c1nc(-c2ncc[s]2)c[o]1 JUGSPWDXQAPNQS-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- OBVXMVKBGRIVEZ-FPYGCLRLSA-N CC/C(/C1OC=C(c2c[o]c[n]2)N1)=C\C Chemical compound CC/C(/C1OC=C(c2c[o]c[n]2)N1)=C\C OBVXMVKBGRIVEZ-FPYGCLRLSA-N 0.000 description 1
- KCXNEKUJNQIGAM-UHFFFAOYSA-N CCC(C)Cc1nnc[o]1 Chemical compound CCC(C)Cc1nnc[o]1 KCXNEKUJNQIGAM-UHFFFAOYSA-N 0.000 description 1
- SHWQKESHXWDQMZ-UHFFFAOYSA-N CCC(CC)c1nc(C2=COCC2)c[o]1 Chemical compound CCC(CC)c1nc(C2=COCC2)c[o]1 SHWQKESHXWDQMZ-UHFFFAOYSA-N 0.000 description 1
- QKPUWAGWEQPXEL-UHFFFAOYSA-N CCC(CC)c1ncc(-c2ncccc2)[o]1 Chemical compound CCC(CC)c1ncc(-c2ncccc2)[o]1 QKPUWAGWEQPXEL-UHFFFAOYSA-N 0.000 description 1
- UMFBKIKEQZLXAX-UHFFFAOYSA-N CCCC(CC)c1nc(-c2c(C)[o]nc2)c[o]1 Chemical compound CCCC(CC)c1nc(-c2c(C)[o]nc2)c[o]1 UMFBKIKEQZLXAX-UHFFFAOYSA-N 0.000 description 1
- GZPCZBJRBBTEHN-UHFFFAOYSA-N CCCC(CC)c1nc(-c2nnc[o]2)c[o]1 Chemical compound CCCC(CC)c1nc(-c2nnc[o]2)c[o]1 GZPCZBJRBBTEHN-UHFFFAOYSA-N 0.000 description 1
- ZLJXPOJIRREUFB-UHFFFAOYSA-N CCCC(CC)c1nc(Cc2c[n](C)cc2)c[o]1 Chemical compound CCCC(CC)c1nc(Cc2c[n](C)cc2)c[o]1 ZLJXPOJIRREUFB-UHFFFAOYSA-N 0.000 description 1
- ILOIOIGZFHGSMS-UHFFFAOYSA-N O=C(CCCCCCc1ccccc1)c1ncc(-c2ccccn2)[o]1 Chemical compound O=C(CCCCCCc1ccccc1)c1ncc(-c2ccccn2)[o]1 ILOIOIGZFHGSMS-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41724702P | 2002-10-08 | 2002-10-08 | |
| PCT/US2003/031975 WO2004033652A2 (en) | 2002-10-08 | 2003-10-08 | Inhibitors of fatty acid amide hydrolase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006502229A JP2006502229A (ja) | 2006-01-19 |
| JP2006502229A5 true JP2006502229A5 (enExample) | 2010-09-09 |
| JP4628789B2 JP4628789B2 (ja) | 2011-02-09 |
Family
ID=32093990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004543576A Expired - Fee Related JP4628789B2 (ja) | 2002-10-08 | 2003-10-08 | 脂肪酸アミド加水分解酵素の阻害剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7662971B2 (enExample) |
| EP (2) | EP1549624B1 (enExample) |
| JP (1) | JP4628789B2 (enExample) |
| KR (1) | KR20050070041A (enExample) |
| CN (1) | CN1703407A (enExample) |
| AT (1) | ATE431342T1 (enExample) |
| AU (1) | AU2003275493A1 (enExample) |
| BR (1) | BR0314980A (enExample) |
| CA (1) | CA2501575A1 (enExample) |
| DE (1) | DE60327640D1 (enExample) |
| EA (1) | EA008767B1 (enExample) |
| ES (1) | ES2325686T3 (enExample) |
| MX (1) | MXPA05003762A (enExample) |
| WO (1) | WO2004033652A2 (enExample) |
| ZA (1) | ZA200501837B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9597318B2 (en) | 2009-10-02 | 2017-03-21 | Avexxin As | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6462054B1 (en) * | 2000-03-27 | 2002-10-08 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| AU2003275493A1 (en) | 2002-10-08 | 2004-05-04 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| FR2865205B1 (fr) * | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866886B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique |
| DE102004039326A1 (de) * | 2004-08-12 | 2006-02-16 | Abbott Gmbh & Co. Kg | Neue medizinische Verwendungen und Verfahren |
| WO2006044617A1 (en) * | 2004-10-15 | 2006-04-27 | The Scripps Research Institute | Oxadiazole ketone inhibitors of fatty acid amide hydrolase |
| EP2937341B1 (en) | 2004-12-30 | 2017-07-05 | Janssen Pharmaceutica N.V. | 4-(benzyl)-piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions |
| US7541359B2 (en) | 2005-06-30 | 2009-06-02 | Janssen Pharmaceutica N.V. | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
| WO2007061862A2 (en) | 2005-11-18 | 2007-05-31 | Janssen Pharmaceutica N.V. | 2-keto-oxazoles as modulators of fatty acid amide hydrolase |
| US7915270B2 (en) * | 2006-02-17 | 2011-03-29 | The Scripps Research Institute | Oxazole ketones as modulators of fatty acid amide hydrolase |
| EP2051964A4 (en) * | 2006-07-28 | 2012-03-07 | Univ Connecticut | INHIBITORS OF FATTY ACID AMIDHYDROLASE |
| US8268817B2 (en) * | 2006-09-08 | 2012-09-18 | The Scripps Research Institute | Substituted oxazole ketone modulators of fatty acid amide hydrolase |
| JP5406828B2 (ja) * | 2007-05-25 | 2014-02-05 | ザ スクリプス リサーチ インスティテュート | 脂肪酸アミドヒドロラーゼの四環式阻害剤 |
| AU2008260496A1 (en) * | 2007-05-31 | 2008-12-11 | The Scripps Research Institute | Tricyclic inhibitors of fatty acid amide hydrolase |
| CA2714743C (en) * | 2008-02-19 | 2017-01-17 | Janssen Pharmaceutica N.V. | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
| WO2009154785A2 (en) * | 2008-06-19 | 2009-12-23 | The Scripps Research Institute | C4-substituted alpha-keto oxazoles |
| WO2010005572A2 (en) * | 2008-07-09 | 2010-01-14 | The Scripps Research Institute | Alpha-keto heterocycles as faah inhibitors |
| JP5698666B2 (ja) * | 2008-08-04 | 2015-04-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｆａａｈの阻害剤として有用なオキサゾール誘導体 |
| US8461159B2 (en) | 2008-11-25 | 2013-06-11 | Jannsen Pharmaceutica BV | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| WO2010068452A1 (en) | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| TWI469979B (zh) * | 2008-12-24 | 2015-01-21 | Bial Portela & Ca Sa | 脂肪酸醯胺水解酶(faah)抑制劑、以及其藥學組成物與用途 |
| AR076687A1 (es) * | 2009-05-18 | 2011-06-29 | Infinity Pharmaceuticals Inc | Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen |
| US20120083476A1 (en) | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| WO2010141809A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase |
| US8906914B2 (en) | 2009-08-18 | 2014-12-09 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid hydrolase |
| US8735406B2 (en) | 2009-09-09 | 2014-05-27 | Dainippon Sumitomo Pharma Co., Ltd. | 8-oxodihydropurine derivative |
| US20120225097A1 (en) | 2009-11-12 | 2012-09-06 | Hawryluk Natalie A | Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah) |
| WO2011085216A2 (en) | 2010-01-08 | 2011-07-14 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating parkinson's disease and restless legs syndrome |
| AU2011209754A1 (en) * | 2010-01-28 | 2012-07-26 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions for the treatment of pain and other indicatons |
| ES2742195T3 (es) | 2010-03-12 | 2020-02-13 | Omeros Corp | Inhibidores de PDE10 y composiciones y métodos relacionados |
| US20130224151A1 (en) | 2010-03-31 | 2013-08-29 | United States Of America | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain |
| US9006433B2 (en) | 2010-04-21 | 2015-04-14 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
| EP3943114B1 (en) * | 2010-09-20 | 2024-08-07 | Sirna Therapeutics, Inc. | Novel low molecular weight cationic lipids for oligonucleotide delivery |
| CN102964311B (zh) * | 2011-09-01 | 2016-03-09 | 大丰海嘉诺药业有限公司 | 一种合成4-甲基-5-烷氧基噁唑的方法 |
| CN104244948B (zh) * | 2012-02-17 | 2016-11-16 | 爱普泰克集团有限公司 | 在炎症性疾病的治疗中使用的用于调节n-酰基乙醇胺的特异性酰胺酶的组合物和方法 |
| AU2014211489A1 (en) | 2013-01-29 | 2015-08-13 | Avexxin As | Antiinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds |
| AU2014342241B2 (en) | 2013-11-01 | 2017-09-14 | Boehringer Ingelheim Animal Health USA Inc. | Antiparasitic and pesticidal isoxazoline compounds |
| NZ716494A (en) | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| NZ716462A (en) | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
| GB201413695D0 (en) | 2014-08-01 | 2014-09-17 | Avexxin As | Compound |
| US20160244860A1 (en) * | 2015-02-20 | 2016-08-25 | Cytec Industries Inc. | Aliphatic-aromatic heterocyclic compounds and uses thereof in metal extractant compositions |
| AU2016250843A1 (en) | 2015-04-24 | 2017-10-12 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| EP3095787A1 (en) * | 2015-05-22 | 2016-11-23 | Universiteit Leiden | Pharmaceutically active compounds as dag-lipase inhibitors |
| WO2017079678A1 (en) | 2015-11-04 | 2017-05-11 | Omeros Corporation | Solid state forms of a pde10 inhibitor |
| GB201604318D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
| JP7531351B2 (ja) | 2019-11-13 | 2024-08-09 | 東京エレクトロン株式会社 | 基板処理方法、基板処理装置、および基板処理システム |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA19269A1 (fr) * | 1980-09-16 | 1982-04-01 | Lilly Co Eli | Perfectionnement relatif a des derives de n-arylbenzamides . |
| US5929247A (en) * | 1994-10-24 | 1999-07-27 | Eli Lilly And Company | Heterocyclic compounds and their preparation and use |
| TW200404789A (en) * | 1999-03-15 | 2004-04-01 | Axys Pharm Inc | Novel compounds and compositions as protease inhibitors |
| US6462054B1 (en) | 2000-03-27 | 2002-10-08 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| US20020103192A1 (en) * | 2000-10-26 | 2002-08-01 | Curtin Michael L. | Inhibitors of histone deacetylase |
| AU2003275493A1 (en) | 2002-10-08 | 2004-05-04 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
-
2003
- 2003-10-08 AU AU2003275493A patent/AU2003275493A1/en not_active Abandoned
- 2003-10-08 KR KR1020057006019A patent/KR20050070041A/ko not_active Withdrawn
- 2003-10-08 JP JP2004543576A patent/JP4628789B2/ja not_active Expired - Fee Related
- 2003-10-08 DE DE60327640T patent/DE60327640D1/de not_active Expired - Lifetime
- 2003-10-08 WO PCT/US2003/031975 patent/WO2004033652A2/en not_active Ceased
- 2003-10-08 CA CA002501575A patent/CA2501575A1/en not_active Abandoned
- 2003-10-08 EA EA200500633A patent/EA008767B1/ru unknown
- 2003-10-08 BR BR0314980-3A patent/BR0314980A/pt not_active IP Right Cessation
- 2003-10-08 ES ES03759771T patent/ES2325686T3/es not_active Expired - Lifetime
- 2003-10-08 CN CNA2003801009944A patent/CN1703407A/zh active Pending
- 2003-10-08 EP EP03759771A patent/EP1549624B1/en not_active Expired - Lifetime
- 2003-10-08 EP EP09006391A patent/EP2093220A3/en not_active Withdrawn
- 2003-10-08 AT AT03759771T patent/ATE431342T1/de not_active IP Right Cessation
- 2003-10-08 MX MXPA05003762A patent/MXPA05003762A/es not_active Application Discontinuation
- 2003-10-08 US US10/528,552 patent/US7662971B2/en not_active Expired - Fee Related
-
2005
- 2005-03-03 ZA ZA200501837A patent/ZA200501837B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9597318B2 (en) | 2009-10-02 | 2017-03-21 | Avexxin As | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006502229A5 (enExample) | ||
| CA2565660A1 (en) | Ortho substituted aryl or heteroaryl amide compounds | |
| WO2005105732A8 (en) | Substituted methyl aryl or heteroaryl amide compounds | |
| WO2005092895A3 (en) | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists | |
| CY1111310T1 (el) | Ενωσεις για την αγωγη μεταβολικων διαταραχων | |
| EA201001455A1 (ru) | Пиридины и пиразины в качестве ингибиторов pi3k (фосфатидилинозиткиназы-3) | |
| WO2003097598A8 (en) | Compound exhibiting pgd 2 receptor antagonism | |
| RU2011143741A (ru) | Производное индолизина и его применение в медицинских целях | |
| TW200508217A (en) | 2-cyanopropanoic acid amide and ester derivatives and methods of their use | |
| MY144209A (en) | Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors | |
| JP2012520247A5 (enExample) | ||
| WO2009135179A3 (en) | The use of solid carrier particles to improve the processability of a pharmaceutical agent | |
| MX2010007977A (es) | Derivados de carboxamidas azabiciclicas, su preparacion y su aplicacion en terapeutica. | |
| EA201290397A1 (ru) | 1,3,4-оксадиазол-2-карбоксамидное соединение | |
| WO2008126901A1 (ja) | 含窒素複素環化合物およびそれを含有する医薬組成物 | |
| CA2700319A1 (en) | Carbonates for use in the preparation of derivatives of dioxan-2-alkyl carbamates | |
| WO2007146124A3 (en) | Deuterated tadalafil derivatives | |
| MX2010007026A (es) | Derivados de triazoloxadiazoles. | |
| WO2008012782A3 (en) | Labelled analogues of halobenzamides as radiopharmaceuticals | |
| CA2722102A1 (en) | Phenylpropionic acid derivative and use thereof | |
| TW200745104A (en) | Multikinase inhibitor | |
| WO2008060787A3 (en) | Methods for treatment of cochlear and vestibular disorders | |
| EP2135622A3 (en) | Compositions for providing an analgesic effect to the skin | |
| CA2514373A1 (en) | N-phenylbenzamide derivatives as drugs for the treatment of copd | |
| JP2002539184A5 (enExample) |